RT3

RT3 is a triple-agonist research peptide acting on GLP-1, GIP, and glucagon receptors. Studied in metabolic and weight-regulation research models. Lyophilized powder. Reconstitute with bacteriostatic water for in-vitro research applications. Store at -20°C. Certificate of Analysis attached to this listing.

Retatrutide acts on three hormone pathways at once: GLP-1, GIP, and glucagon, affecting appetite, blood sugar, and calorie burning simultaneously. [Source: Peptide Dosing Protocols]

Retatrutide acts as a triple agonist, targeting three hormone pathways: GLP-1, GIP, and glucagon. This multi-pathway approach influences appetite regulation, blood sugar control, and metabolic rate, thereby promoting weight loss and improving metabolic outcomes. The mechanism involves enhancing insulin secretion in response to meals, suppressing glucagon release, and slowing gastric emptying, which collectively contribute to reduced appetite and increased energy expenditure.

In clinical trials, retatrutide has shown significant efficacy in weight loss. For instance, in the Phase 3 TRIUMPH-4 trial, participants receiving the 12 mg dose experienced an average weight loss of 28.7% at 68 weeks. This trial also reported improvements in pain scores for participants with knee osteoarthritis, indicating additional benefits beyond weight loss. The pharmacokinetics of retatrutide, as established in Phase 1 studies, indicate a half-life of approximately 6 days, supporting its once-weekly dosing regimen. This prolonged half-life is attributed to albumin binding via a C20 fatty diacid attachment, which enhances its stability and efficacy.

The dosing protocol for retatrutide is designed as a gradual titration, starting at 1 mg and increasing every four weeks to allow the body to adjust. This careful escalation is crucial as it minimizes gastrointestinal side effects, which are common during the initial phases of treatment. The Phase 2 trial data demonstrated that participants who adhered to the slow titration schedule experienced fewer adverse effects and better overall tolerance to the medication. The importance of pacing in titration is underscored by findings that show a significant increase in gastrointestinal side effects when doses were escalated too quickly, emphasizing the need for a structured approach to dosing. [Source: Peptide Dosing Protocols]

COA: View certificate (batch TET-4903-A) →

Teton Labs product catalog · research-use compound data.